Interferon is currently considered to be the only accepted effective treatment for chronic viral hepatitis.
Abstract
Interferon is currently considered to be the only accepted effective treatment for chronic viral hepatitis. A history of the treatment of chronic hepatitis B and C before the use of interferon is presented here. Hepatitis B virus does not seem to be directly cytopathic and the disease is known to be modulated largely by the host's immune response. Experience with immunosuppressant and immunostimulant drugs and a wide variety of antiviral agents, however, has indicated that none of these are of any benefit in patients with chronic hepatitis B, with the possible exception of adenine arabinoside. In view of the much more recent identification of the hepatitis C virus, studies of therapy for chronic hepatitis C are inevitably less extensive. A pilot study using acyclovir in patients with chronic non-A, non-B hepatitis did not show any benefit, although the treatment period may have been too short for the results to be conclusive. The only agent other than alpha interferon to be tried in chronic hepatitis C is ribavirin, which may have some activity. Many of the agents studied in chronic hepatitis B should also be investigated for the treatment of patients with chronic hepatitis C.
(Gut 1993; supplement: S69-S73) In reviewing the history of the treatment of chronic viral hepatitis one has to keep in mind that treatment of any disease depends on a precise understanding of pathogenetic mechanisms and the availability of drugs able to interfere with these. As with other diseases, there has been an explosion in knowledge on Side effects with ARA-A are common and dose related. The most relevant clinical side effect is neuromuscular toxicity, which is associated with severe pains mainly in the paravertebral and lower limb muscles. Combination with human leukocyte interferon has been shown to enhance toxicity and does not improve the overall efficacy.22
Acyclovir and descyclovir Acyclovir and descyclovir, the oral pro-drug, are non-cyclic guanosine analogues that specifically inhibit viral but not host cell DNA synthesis. They inhibit DNA polymerase activity in Peking ducks infected with hepatitis B. Two small, randomised controlled studies have been performed in patients with chronic hepatitis B, where acyclovir showed transient inhibition of HBV replication but no significant effect on the HBeAg seroconversion rate. 23 24 The enhancement of the antiviral effects of alpha lymphoblastoid interferon by acyclovir and possibly by descyclovir25 26 has to be confirmed by appropriate trials.
3'-azido-3'deoxythymidine (Zidovudine) and Suramin Since reverse transcriptase activity is a prerequisite for HBV replication, inhibitors of reverse transcriptase may be useful for the treatment of hepatitis B. Zidovudine and suramin (a drug used for the treatment of trypanosomiasis) inhibit HBV replication in vitro. Zidovudine has decreased HBV replication in patients with hepatitis B.27 Suramin was tried in three patients with severe hepatitis B but was associated with unacceptable, life threatening side effects.28
Trisodium-phosphonoformat (Foscarnet) Foscarnet inhibits HBV-DNA polymerase in vitro and has been administered to a few patients with fulminant hepatic failure due to hepatitis B. It seemed to decrease mortality in these patients29 3 and, in the largest study, six of eight patients survived. 30 No reports are available on the potential effects of this drug in patients with chronic hepatitis B.
Extract ofphyllanthus ninuri (amarus) An extract of this plant had been used traditionally in southern India to treat jaundice, and has been shown to inhibit viral replication in woodchuck hepatitis.3' In a randomised, placebo-controlled study using the dried, powdered, and sterilised plant, high rates of HBsAg seroconversion were observed. No serious side effects were reported. However, only incomplete follow up data were 32 given.
Ribavirin
Ribavirin is a nucleotide analogue which inhibits the in vivo synthesis of DNA. In a short-term trial, ribavirin failed to decrease HBV-DNA polymerase activity or HBsAg concentrations, and had no effect on liver function in six HBsAg positive patients. 33 In the light of the apparent beneficial effects of this drug in chronic hepatitis C,34 it has recently been re-evaluated in the treatment of hepatitis B, and now seems to be effective (Fried et al (abstract presented at the Annual Meeting of the American Gastroenterological Association, San Francisco, 1992).
OTHER DRUGS USED FOR TREATMENT OF CHRONIC HEPATITIS B
D-penicillamine D-penicillamine, a chelating agent, is the treatment of choice in patients with Wilson's disease. It has also been used in primary biliary cirrhosis. In addition to its copper-chelating actions, it has anti-inflammatory properties and may stimulate fibre removal from the liver. It has been tried successfully in some patients with chronic hepatitis35 but not in controlled trials.
Hepatoprotective agents Hepatoprotective agents are substances which are able to prevent toxic liver cell injury. They are used widely in Europe for the treatment of a variety of liver diseases. (+)-Cyanidanol-3, a flavoid extracted from the plant Uncaria gambir, was tested in a large, double blind study involving 338 HBeAg positive patients.
It was found to enhance the HBeAg seroconversion rate after 14 weeks of treatment. 36 However, in another controlled trial which included various forms of chronic active hepatitis, no effects of this drug were observed in HBsAg-positive patients. 37 Similarly, subgroup analysis of a large, placebo-controlled prospective trial in patients with various forms of liver cirrhosis, indicated that silymarin, an extract from the milk thistle fruit, Silybum marianum Gaertneri L, did not affect the outcome of HBsAg positive patients.38
Treatment of chronic hepatitis C Hepatitis C virus (HCV) infection is responsible for most chronic cases of non-A, non-B (NANB) hepatitis. Because HCV was discovered only four years ago, the history of its treatment is very short. In 1984, Alter and Hoofnagle concluded that there was no effective treatment available for chronic NANB hepatitis.39 Because of the lack of serological tests, systematic treatment protocols could not be performed. Only a few drugs were tested for their ability to improve chronic, blood transfusion associated NANB hepatitis before the discovery of antibodies against HCV in 1989. In a pilot study, five patients with NANB hepatitis received a short treatment course of acyclovir. None of the patients tested improved.39 In the light of our current knowledge that antiviral treatment has to be administered to patients with chronic hepatitis C for many months to be effective, this short treatment may not have been sufficient to conclude that acyclovir is ineffective in the treatment of hepatitis C. In 1986, Hoofnagle reported the beneficial effects of interferon alfa in a pilot study of the treatment of chronic NANB hepatitis.4' This enthusiastic study prompted many randomised, controlled trials worldwide, which have since proved the efficacy of this treatment. 42 43 Another successful approach may be antiviral treatment with ribavirin.34 It should be stressed, however, that many of the agents which were studied in chronic hepatitis B need also to be investigated in the treatment of chronic hepatitis C.
Conclusions
Interferon remains the only accepted treatment for chronic viral hepatitis caused by either HBV or HCV. Despite a large number of trials with a wide range of agents, no other effective treatment has yet been confirmed for patients with chronic hepatitis B. In chronic hepatitis C, it seems that ribavirin may have some benefit, but studies with other agents are awaited.
